Cane Capital Partners’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.03M Sell
2,433
-826
-25% -$329K 0.38% 59
2026
Q2
$1.18M Buy
3,259
+1,377
+73% +$471K 0.47% 52
2026
Q1
$662K Sell
1,882
-203
-10% -$72.4K 0.29% 64
2025
Q4
$682K Hold
2,085
– – 0.27% 73

Other funds holding AMGN

Cane Capital Partners's AMGN Position: Q3 2026 in Review

Cane Capital Partners reduced its Amgen (AMGN) stake by 25% in Q3 2026, selling an estimated $329K and leaving 2,433 shares worth $1.03M. The position accounts for 0.38% of the portfolio, ranked #59.

Cane Capital Partners first reported a position in AMGN in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.18M in Q2 2026. 3,275 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Cane Capital Partners held 2,433 shares of Amgen worth $1.03M as of Q3 2026.
  • Cane Capital Partners sold 826 Amgen shares in Q3 2026, an estimated $329K.
  • Amgen made up 0.38% of Cane Capital Partners's portfolio in Q3 2026, its #59 holding.
  • Cane Capital Partners first reported a position in Amgen in Q4 2025 and has held it in 4 quarters since.
  • Cane Capital Partners's Amgen position peaked at $1.18M in Q2 2026.
  • 3,275 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Cane Capital Partners's 13F filing for Q3 2026, filed 23 Oct 2026.